Business Development

Partnerships are an integral part of the business of Statens Serum Institut.

Business Development in the Division of Vaccine is focused on identifying, entering and maintaining successful partnerships within our key areas of interest:   

  • Tuberculosis 
  • Chlamydia 
  • Delivery, Formulation and Adjuvants

We are open to mutually beneficial partnerships with academia, biotech companies and pharmaceutical industry in order to establish both scientific collaborations and value maximizing commercial partnerships.

We are actively seeking out-licensing opportunities for our proprietary technologies and we are continuously searching  for innovative technologies supplementing our existing technologies and R&D programs.

Currently, SSI is part of several global alliances, e.g. out-licensure of tuberculosis antigens to several key players within tuberculosis in-vitro diagnostics (e.g. Qiagen and Oxford Immunotec), as well as a partnership with Sanofi-Pasteur for the development of a tuberculosis vaccine.